SkinBioTherapeutics (SBTX) Price & Analysis

Compare

18 Followers

SBTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range9.00p - 27.50p

Previous CloseN/A

Volume282.34K

Average Volume (3M)905.60K

Market Cap

£36.23M

Enterprise Value41.05M

Total Cash (Recent Filing)£1.24M

Total Debt (Recent Filing)£1.03M

Price to Earnings (P/E)―

Beta0.14

Next Earnings

Dec 04, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding258,779,450

10 Day Avg. Volume562,709

30 Day Avg. Volume905,604

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£16.00

Price Target Upside11.27% Upside

Rating ConsensusModerate Sell

Number of Analyst Covering1

SkinBioTherapeutics News

SkinBioTherapeutics Reports Strong FY25 Growth and Strategic Expansion

SkinBioTherapeutics ( ($GB:SBTX) ) just unveiled an update. SkinBioTherapeutics plc announced a trading update for FY25, revealing expected...

4d ago

SkinBioTherapeutics Secures UK Distribution Deal with Superdrug

The latest announcement is out from SkinBioTherapeutics ( ($GB:SBTX) ). SkinBioTherapeutics has announced an exclusive UK commercial agreement...

2M ago

David Brierwood Increases Stake in SkinBioTherapeutics

The latest announcement is out from SkinBioTherapeutics ( ($GB:SBTX) ). David Campbell Brierwood has increased his voting rights...

2M ago

SkinBioTherapeutics Raises £4.2 Million Through Share Issuance

SkinBioTherapeutics ( ($GB:SBTX) ) has shared an announcement. SkinBioTherapeutics plc has successfully raised approximately £4.2 million through a...

2M ago

SkinBioTherapeutics Launches £0.62m Retail Offer Amid Broader Fundraising Efforts

SkinBioTherapeutics ( ($GB:SBTX) ) has shared an update. SkinBioTherapeutics plc has announced a retail offer through the Winterflood...

2M ago

SkinBioTherapeutics Secures Superdrug Deal and Raises £4.1m

SkinBioTherapeutics ( ($GB:SBTX) ) has shared an update. SkinBioTherapeutics has signed an exclusive UK commercial agreement with Superdrug...

2M ago

SkinBioTherapeutics Appoints New Adviser and Broker

SkinBioTherapeutics ( ($GB:SBTX) ) just unveiled an announcement. SkinBioTherapeutics plc has appointed Singer Capital Markets as its Nominated...

3M ago

SkinBioTherapeutics Announces Change in Major Holdings

SkinBioTherapeutics ( ($GB:SBTX) ) has provided an announcement. SkinBioTherapeutics PLC, a company involved in the biotechnology sector, has...

3M ago

SkinBioTherapeutics Announces Change in Voting Rights Structure

The latest update is out from SkinBioTherapeutics ( ($GB:SBTX) ). SkinBioTherapeutics PLC has announced a change in the...

3M ago

SkinBioTherapeutics Announces Warrant Exercise and Share Admission

SkinBioTherapeutics ( ($GB:SBTX) ) has provided an update. SkinBioTherapeutics announced the exercise of warrants by Macquarie for 1,099,244...

4M ago

SBTX FAQ

What was SkinBioTherapeutics PLC’s price range in the past 12 months?

SkinBioTherapeutics PLC lowest share price was 9.00p and its highest was 27.50p in the past 12 months.

What is SkinBioTherapeutics PLC’s market cap?

SkinBioTherapeutics PLC’s market cap is £36.23M.

When is SkinBioTherapeutics PLC’s upcoming earnings report date?

SkinBioTherapeutics PLC’s upcoming earnings report date is Dec 04, 2025 which is in 108 days.

How were SkinBioTherapeutics PLC’s earnings last quarter?

Currently, no data Available

Is SkinBioTherapeutics PLC overvalued?

According to Wall Street analysts SkinBioTherapeutics PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SkinBioTherapeutics PLC pay dividends?

SkinBioTherapeutics PLC does not currently pay dividends.

What is SkinBioTherapeutics PLC’s EPS estimate?

SkinBioTherapeutics PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SkinBioTherapeutics PLC have?

SkinBioTherapeutics PLC has 258,779,450 shares outstanding.

What happened to SkinBioTherapeutics PLC’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of SkinBioTherapeutics PLC?

Currently, no hedge funds are holding shares in GB:SBTX

SkinBioTherapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-63.28%

Trailing 12-Months

Asset Growth

73.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SkinBioTherapeutics PLC

SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

SkinBioTherapeutics (SBTX) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

SBTX Stock 12 Month Forecast

Average Price Target

16.00p

▲(11.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"8p","25":"25p","12.25":"12.25p","16.5":"16.5p","20.75":"20.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">16.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">16.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">16.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,12.25,16.5,20.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.88,18.658461538461538,18.436923076923076,18.215384615384615,17.993846153846153,17.77230769230769,17.55076923076923,17.32923076923077,17.107692307692307,16.886153846153846,16.664615384615384,16.443076923076923,16.22153846153846,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.88,18.658461538461538,18.436923076923076,18.215384615384615,17.993846153846153,17.77230769230769,17.55076923076923,17.32923076923077,17.107692307692307,16.886153846153846,16.664615384615384,16.443076923076923,16.22153846153846,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.88,18.658461538461538,18.436923076923076,18.215384615384615,17.993846153846153,17.77230769230769,17.55076923076923,17.32923076923077,17.107692307692307,16.886153846153846,16.664615384615384,16.443076923076923,16.22153846153846,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.25,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.88,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.75,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.62,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.75,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.5,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.75,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.75,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.1,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.5,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.25,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.88,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >